Moleculin Biotech Inc (NASDAQ:MBRX) – Investment analysts at Oppenheimer issued their Q3 2019 earnings per share estimates for Moleculin Biotech in a report issued on Wednesday, October 16th. Oppenheimer analyst K. Degeeter anticipates that the company will post earnings of ($0.09) per share for the quarter. Oppenheimer currently has a “Outperform” rating and a $2.00 price target on the stock. Oppenheimer also issued estimates for Moleculin Biotech’s Q4 2019 earnings at ($0.10) EPS, FY2019 earnings at ($0.42) EPS, Q1 2020 earnings at ($0.11) EPS, Q2 2020 earnings at ($0.12) EPS, Q3 2020 earnings at ($0.12) EPS, Q4 2020 earnings at ($0.13) EPS and FY2020 earnings at ($0.48) EPS.
Several other research firms also recently commented on MBRX. Maxim Group set a $3.00 price objective on shares of Moleculin Biotech and gave the stock a “buy” rating in a report on Tuesday, August 20th. ValuEngine raised shares of Moleculin Biotech from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $4.33.
MBRX opened at $1.14 on Monday. The company has a 50 day moving average of $1.10 and a 200 day moving average of $1.16. The company has a market cap of $51.08 million, a PE ratio of -2.24 and a beta of 1.96. Moleculin Biotech has a 12 month low of $0.78 and a 12 month high of $3.15. The company has a current ratio of 2.11, a quick ratio of 2.11 and a debt-to-equity ratio of 0.01.
Moleculin Biotech (NASDAQ:MBRX) last released its quarterly earnings data on Friday, August 16th. The company reported ($0.03) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.07.
Large investors have recently made changes to their positions in the business. Renaissance Technologies LLC increased its holdings in shares of Moleculin Biotech by 430.4% during the second quarter. Renaissance Technologies LLC now owns 833,664 shares of the company’s stock worth $1,042,000 after buying an additional 676,500 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Moleculin Biotech by 134.8% during the second quarter. BlackRock Inc. now owns 112,572 shares of the company’s stock worth $141,000 after buying an additional 64,632 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Moleculin Biotech by 235.4% during the second quarter. Vanguard Group Inc. now owns 2,680,010 shares of the company’s stock worth $3,350,000 after buying an additional 1,880,961 shares in the last quarter. Finally, Morgan Stanley increased its holdings in shares of Moleculin Biotech by 151.7% during the second quarter. Morgan Stanley now owns 31,411 shares of the company’s stock worth $39,000 after buying an additional 18,933 shares in the last quarter. 9.41% of the stock is owned by hedge funds and other institutional investors.
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.
Further Reading: Is the QQQ ETF safe?
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.